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ABSTRACT
Background: Limited data are available on the prevalence of oncogenic driver 
mutations in Caucasian populations, and especially in Europeans.
Aim: To evaluate the targetable mutational spectra in unselected patients with 
lung adenocarcinoma in routine clinical practice from several French hospitals, using 
the same molecular platform.
Patients and Methods: Samples from 2,219 consecutive patients with histologically-
proven advanced lung adenocarcinoma were centrally analysed at a referenced and 
certified diagnostic platform in order to test for activating and resistance mutations 
in EGFR, KRAS, BRAF, ERBB2 and PI3KCA. Demographic and clinical features were 
retrieved from the medical charts. Multivariate binary logistic regression was used to 
determine the independent predictive factors for the occurrence of specific mutations, 
in the whole study population or in selected subgroups.
Findings: The overall respective incidence of EGFR, KRAS, BRAF, ERBB2 and PI3KCA 
mutations was 10.5%, 0.9%, 25%, 1.5%, 2.1% and 1.4%, in our study sample including 
87.4% white Caucasians, 10.8% Africans and 1.8% Asians; 60.6% men, 30.7% never 
smoker (median age: 68.3 years). Ethnicity was an independent predictor for EGFR, 
www.impactjournals.com/oncotarget/ Oncotarget, Advance Publications 2017
Oncotarget2www.impactjournals.com/oncotarget
KRAS and ERBB2 gene abnormalities. In all cases, a significantly higher prevalence of 
targetable EGFR and ERBB2, and a lower prevalence of resistance KRAS mutations were 
observed in African women as compared to African men or Caucasians.
Conclusions: In real life conditions of routine genetic testing, we have identified 
subsets of patients with specific targetable activating somatic mutations according to 
ethnicity, who could preferentially benefit from anti-EGFR and anti-ERBB2 targeted 
therapies.
INTRODUCTION
The identification of EGFR mutations as activating 
mutations conferring sensitivity to anti-EGFR therapies 
like gefitinib or erlotinib was firstly reported in 2004 by 2 
groups studying American and Asian patient populations 
[1–3]. They also observed that EGFR mutations in exons 
18 to 21 were more prevalent in Japaneses (30%) as 
compared to Caucasians (only 7%). In 2009, the IRESSA 
Pan-Asia Study (IPASS), which compared the EGFR 
tyrosine kinase inhibitor (TKI), gefitinib, with carboplatin-
paclitaxel cytotoxics, was conducted on patients of Asian 
descent with adenocarcinoma, as a mutation-enriching 
strategy in the study population. The trial demonstrated 
that gefitinib was associated with a 12-month progression-
free survival rate of 24.9%, in comparison to 6.7% in the 
chemotherapy arm [4]. This key study has authorized 
the use of gefitinib as first-line therapy in patients whose 
metastatic adenocarcinoma carries EGFR mutations.
Women, and especially never smokers, also exhibit 
a higher EGFR mutational frequency, especially in Asian 
never smokers, with a rate ranging between 48% and 
75.3% [5–8].
A number of institutions worldwide have integrated 
EGFR molecular profiling into routine lung cancer diagnosis 
to personalize treatment decisions, and especially the use of 
TKIs [9]. The vast amount of genomic information has shed 
light on high variations in EGFR mutational frequencies, 
ranging from 7% to 40.1% within the Asian population [10–
17]. EGFR mutation frequency was lower in populations not 
of Asian origin, with a high genetic heterogeneity around 
the world [18]. Indeed, in Latin populations, either in Spain 
or in Latin America, the frequency of EGFR mutations 
in NSCLC has been reported to vary from 16.6% to 37% 
[19, 20]. In America where Latin-Americans or African-
Americans with NSCLC are included in the screening for 
EGFR, the frequency of EGFR testing is approximately 
25% [21–26]. In Europe, except for Spain, the frequency of 
EGFR mutations is the lowest reported, in approximately 
10% of metastatic or advanced lung adenocarcinomas 
[27–32]. Nonetheless, only limited data on the prevalence 
of EGFR mutations are available in Caucasian populations, 
and especially in Europeans. Moreover, there are few 
data on the mutation rates of targetable oncogenic BRAF, 
ERBB2, KRAS or PI3KCA mutations across worldwide 
populations [33–35]. Corresponding information regarding 
the African population remains deficient except for African-
Americans [21–26], although North Africans represent an 
important proportion of NSCLC patients daily treated in 
French hospitals.
The aim of our study was to analyze the mutational 
rate of EGFR, KRAS, BRAF, ERBB2 and PI3KCA in a 
large cohort of 2,219 unselected French patients presenting 
in routine clinical practice for first line treatment decision 
of metastatic or recurrent lung adenocarcinoma.
RESULTS
Characteristics of the French cohort of 2,219 
patients with lung adenocarcinoma testing for 
EGFR mutations
All tumours were adenocarcinomas, and all 
patients had advanced stage disease. Eighty percent of 
the samples analysed were biopsies from lung tumors 
(through transbronchial fibroscopy or percutaneous 
scan-guided biopsy); the remaining 20% were surgical 
specimens or biopsies from metastatic lesions, mainly in 
supradiaphragmatic lymph nodes.
Patients were diagnosed at a median age of 68.3 years 
(range, 26.6 to 93.7 years; standard deviation, 11.1 years). 
There was a higher proportion of men (60.6% men vs 39.4% 
women) and of tobacco-exposed individuals (48.2% current 
smokers; 21.1% former smokers; 30.7% never smokers), 
with a median of 20 packs year for the smokers (Table 1).
Among the 2,219 consecutive patients that constitute 
our study population, most of them were Caucasian (1,940 
patients; 87.4%); those of African ancestry (240 patients; 
10.8%) were more common than those of Asian origin (39 
patients; 1.8%).
Mutational spectrum of the study population
KRAS mutations were altogether the most common 
genetic abnormalities observed (Figure 1). Indeed, a 
fourth of the samples was mutated for KRAS exon 2 or 3 
(95% Confidence Limits: 23.2%-26.8%), whereas 58.9% 
of the samples (95% CL: 56.9%-61.0%) did not show 
any genetic alteration within our panel. The observed 
prevalence of activating EGFR mutations (activating 
common and uncommon mutations in exon 18 to 21) 
was 10.5% (95% CL: 9.2%-11.8%); EGFR resistance 
mutations in exon 20 were present in only 0.9% of the 
samples (95% CL: 0.5% - 1.3%). Respective prevalence 
of BRAF, PI3KCA or ERBB2 alterations was 1.5% (1.0%-
2.0%), 2.1% (1.5%-2.7%) and 1.4% (0.9%-1.9%).
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Frequency of EGFR mutations
Activating EGFR mutations have to date the most 
prominent therapeutic role in the clinical management of 
NSCLC. The independent predictors of activating EGFR 
mutations included gender, smoking status, age and ethnic 
origin (Table 2). Thus, activating EGFR mutations were 
almost thrice more common in women (17.7%) than in 
men (6.1%), and in non-smokers (74.5%) than in smokers 
(current: 26.2%; former: 25.7%). Older patients were 
also more likely to have a tumor with activating EGFR 
mutation, with a prevalence per age quartiles increasing 
from 7.7% in younger patients (< 61 years) to 15.6% in 
older patients (> 76 years). Patients of Asian descent had 
the highest prevalence of activating EGFR mutations 
(36.1%), in comparison to Caucasians (10.2%) or 
Africans (9.3%). However, the prevalence of mutated 
EGFR according to gender was more dissimilar in African 
patients (males: 5.2%; females: 29.3%) than in Caucasians 
(5.7% in men and 16.8% in women).
Subtypes of EGFR mutations
Subtypes of EGFR mutations were overall distributed 
as follows: L858R was observed in 63 patients (2.8%), 
del19 in 81 patients (3.7%), T790M and other rare ones in 
13 (0.6%) patients each. However, the incidence of each 
mutation differed according to ethnicity. Thus, the ratio 
del19/L858R was 1.31 in Europeans, 2.00 in Asians and 
0.86 in Africans, respectively. Additionally, the relative 
frequency of T790M among all EGFR mutations was 5.6% 
in Europeans, 14.3% in Asians, and 21.1% in Africans.
Frequency (prevalence) of KRAS mutations
KRAS mutations were the most commonly 
encountered genetic alterations in our study populations, 
and age and ethnic origin independently predicted for 
their occurrence (Table 2). Thus, their prevalence dropped 
from 28.1% in younger patients to 20.3% in older ones. 
Caucasians had the highest prevalence of KRAS mutations 
(26.3%), whilst Asians had the lowest (7.7%); Africans 
displayed an intermediate prevalence (17.2%).
The prevalence of mutated KRAS according to 
gender was most similar in patients with Caucasian 
background (males: 25.2% and females: 28.2%), 
intermediate in Africans (18.8% in men and 11.9% in 
women) and most dissimilar in Asians (males: 13.0%; 
females: 0%).
Frequency of BRAF, PI3KCA and ERBB2 
mutations
Amidst the least frequent mutations, no independent 
predictive factor was identified for BRAF mutations, 
whereas increasing age had a positive predictive value 
for the occurrence of PI3KCA mutations (HR: 1.048; 
95% CL: 1.018 to 1.078; p=0.002). Interestingly, ethnic 
origin was the only independent predictive factor for 
ERBB2 mutations (Table 2). Indeed, this genetic alteration 
occurred in 8.1% of Asian patients, in 3.3% of African 
ones, and in only 1.0% of those of Caucasian descent.
The prevalence of mutated ERBB2 according to 
gender was rather similar in patients with Asian (men: 
8.7%; women: 7.7%) or Caucasian (0.9% and 1.3%) 
background, and fairly different in African patients (males: 
2.1%; females: 9.3%).
Ethnic demographics
The observation that the mutational phenotype in 
patients from Africa appeared intermediate between that 
Table 1: Clinical and demographic features of the whole study sample (N=2, 219)
Feature N %
Gender Male 1,345 60.6
Female 874 39.4
Smoking status Never 633 28.5
Former 434 19.6
Current 993 44.7
Unknown 159 7.2
Continent Europe 1,940 87.4
Asia 39 1.8
Africa 240 10.8
Age Median 68.3
1st-3rd quartile 61.0-76.5
Range 26.6-93.7
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of Europeans and that of Asians prompted us to explore 
more in depth the effect of ethnic origin on the mutational 
phenotype of NSCLC patients treated in France. Hence, 
we focused on the subgroup of patients from Africa, 
which is often underrepresented and overlooked in 
Western studies in NSCLC, despite it accounts for a fairly 
substantial proportion of patients treated for NSCLC (in 
our study, 10.8%).
The clinical and demographic features of the 240 
patients from Africa are summarized in Table 3. Thus, as 
compared to the other ethnic subgroups, African patients 
were more commonly males (81.7% versus 58.1%; p 
<0.0001) and smokers (never: 14.3% versus 35.1%; 
p=0.018), whereas no age difference with the rest of the 
patients was observed (median: 68.9 versus 68.2 years).
The mutational spectrum of African patients is 
shown in Figure 2. This ethnic group displayed a higher 
prevalence of EGFR resistance mutations (p=0.014), yet 
not of EGFR activating mutations (p=0.53), a higher 
prevalence of ERBB2 alterations (p=0.007); a lower 
prevalence of KRAS (p=0.004) and BRAF (p=0.045) 
mutations, and a not significant difference in PI3KCA 
(p=0.14).
However, subgroup analysis according to gender 
suggested that African women have a peculiar mutational 
spectrum, with an independently higher risk of presenting 
EGFR activating (HR: 2.05; 95% CL: 1.02-4.12; p=0.044) 
and EGFR resistance mutations (HR: 4.16; 95% CL: 1.17-
14.77; p=0.028). Additionally, African women displayed a 
notably higher risk of having cancers harbouring ERBB2 
mutations (HR: 8.01; 95% CL: 2.41-26.68; p=0.001), and 
a lower risk of KRAS mutations (HR: 0.34; 95% CL: 0.13-
0.89; p=0.027).
The observed prevalence of the main mutations, in 
man and women from the three ethnic groups is depicted 
in Figure 3.
DISCUSSION
We examined 2,219 unselected patients treated in 
hospitals in Paris and suburbs (France) for metastatic or 
recurrent lung adenocarcinoma, who were systematically 
tested for EGFR and other targetable driver mutations 
in the daily clinical setting. We found, similarly to other 
groups, an overall rate of activating EGFR mutations of 
10.5% [18, 32]. KRAS was the most prevalent mutation 
with 25.0% of positive cases, whereas BRAF, ERBB2 
and PI3KCA mutations were relatively uncommon, 
with 1.5, 1.4, and 2.1% mutational rates, respectively. 
Gender, smoking habits, but also ethnicity, alone and 
combined, appeared to influence these figures. Indeed, 
in the subpopulation of migrants from Africa (1st or 2nd 
generations), the molecular phenotype appeared peculiar, 
with prominent gender-specific differences. For example, 
EGFR activating and resistance mutation rates were as 
high as 29.3% and 26.7% in African women, respectively, 
whilst respective rates being as low as 5.2% and 7.1% in 
African men. Similarly, and very interestingly, ERBB2 
was mutated in 9.3% of African women, and in only 2.1% 
of men from Africa. Overall, rates of PI3KCA mutations 
were more frequent in females than in males from Africa, 
although not to a significant extent. These data could 
Figure 1: Chart representing the proportions of patients with each mutation of the spectrum analysed, within the 
whole study sample (N=2, 219).
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Table 3: Clinical and demographic features of the subset from Africa (N=240)
Feature N %
Gender Male 196 81.7
Female 44 18.3
Smoking status Never 34 14.3
Former 41 17.1
Current 165 68.6
Age Median 68.9
1st-3rd quartile 59.6-75.1
Range 38.1-92.0
Table 2: Independent predictive factors for EGFR activating mutation, KRAS mutation and ERBB2 endoduplication 
in the whole study sample (multivariate analysis)
Parameter HR 95% CL p
EGFR activating mutation
Continent <0.0001
Europe 1
Asia 5.65 2.67-12.0 <0.0001
Africa 1.27 0.77-2.10 0.35
Smoking status <0.0001
Never 1
Former 0.12 0.04-0.32 <0.0001
Current 0.12 0.06-0.27 <0.0001
Gender <0.0001
Male 1
Female 3.50 2.59-4.71
Age 1.03 1.02-1.05 <0.0001
KRAS mutation
Continent 0.01
Europe 1
Asia 0.24 0.07-0.79 0.019
Africa 0.59 0.41-0.84 0.004
Age 0.986 0.977-0.994 0.01
ERBB2 endoduplication
Continent <0.0001
Europe 1
Asia 9.96 2.77-35.8 <0.0001
Africa 4.32 1.80-10.4 0.001
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suggest that African women have a more genetically 
instable phenotype, even though KRAS was not more 
frequently mutated in women than in men from Africa. 
However, KRAS was altogether less frequently mutated in 
patients from Africa (17%) than in the global population 
(25%).
In Europe, the first reports of lung-cancer–specific 
EGFR mutations were described in Italy, and showed 
EGFR mutations in 10% of 375 lung adenocarcinomas 
[27], whereas in Spain it was described a rate of EGFR 
mutations of 16.6% [19]. Since the development of 
systematic EGFR mutational status testing in metastatic 
Figure 2: Chart representing the mutational spectrum of the subset of patients of African descent (N=240).
Figure 3: Prevalence of ERBB2 (red), EGFR-activating (blue) and KRAS (yellow) mutations, in the subgroups 
determined by gender and ethnicity.
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adenocarcinomas to identify patients who can benefit from 
first line TKIs, several reports have shown that the EGFR 
mutations prevalence is approximately 10% in Northern 
European populations [27–32]. In North America, several 
recent reports on the EGFR testing show a generally 
higher prevalence (approximately 25%), but most of 
them include a variety of heterogeneous racial groups and 
smoking habits [8, 26]. Similarly, it has been reported that 
the prevalence of EGFR mutations is 2 to 3-fold higher 
in Asians, with differences between Eastern and Western 
regions observed [10–17]. In the French population 
studied here, the subgroup from Asia was relatively 
underrepresented. However, in this ethnic subgroup 
counting 39 patients, we observed the expected higher 
EGFR mutational rate as compared to that in Caucasians, 
with a prevalence of 36.1%. Similarly, we observed, as 
already previously reported, that women and non-smokers 
exhibited more frequently EGFR activating mutations.
Thus, the analysis per ethnicity in our French 
unselected population showed similar EGFR mutational 
rates between Africans and Caucasians, despite an 
almost halved proportion of never smokers and a double 
proportion of males in our subgroup of patients of African 
descent.
Contrariwise, the KRAS mutational rate of Africans 
(17.2%) was intermediate between the highest one in 
Caucasians (26.3%) and the lowest one in Asians (7.7%). 
These results corroborate previous results showing that 
KRAS mutations are less common in Asians compared to 
Caucasians [6, 36, 37].
Similarly, the prevalence of ERBB2 mutation 
in patients of African origin (3.3%) was intermediate 
between that observed in Asian (8.1%) and Caucasian 
(1.0%) patients.
However, although the global prevalence of 
ERBB2 mutations was 1.4%, figure consistent with recent 
publications [38–41], the mutation rate of 3.3% observed 
here in the African population reaches an interesting 
threshold to be systematically screened for, in this selected 
subgroup of patients. This is even more clinically relevant 
since recent studies demonstrated a significant therapeutic 
benefit of trastuzumab (an anti-ERBB2 mAb) and of 
newer TKIs, such as afatinib and neratinib, which target 
both EGFR and ERBB2, in selected patients with lung 
adenocarcinoma [38, 42–46].
The prevalence of EGFR mutation has been 
recently reported in African populations. Errihani et al. 
[47] have studied a Moroccan population of 137 patients 
with an overall frequency of the EGFR mutations of 
21%. However, they reported a high incidence of EGFR 
mutations with an unusual incidence of exon 21 L858R/
exon 19 frameshift base pair deletions or exon 20 
mutations. Nonetheless, they tested tumors on the French 
continent in a single laboratory, and did not mention to 
be from consecutive patients. We could therefore suspect 
a biased selection of patients presenting in Moroccan 
university hospitals who have then benefited abroad from 
oncogenetic testing. Other reports in American studies 
analysing African Americans subpopulations show a 
lower frequency of somatic driver mutations than in 
Caucasians [21]. We observed, nevertheless, that patients 
of African descent have a relatively higher incidence of 
T790M mutations (more than 4-fold), and a shift towards 
more frequent L858R rather than del19 (1.5-fold), in 
comparison with European patients.
Interestingly, some studies in Latin America 
populations report higher incidence of EGFR mutations 
than that found in Europe. A recent study shows an overall 
frequency of EGFR mutations of 26% in Latin America 
(from 14.4% in Argentina to 31% in Costa Rica) [48]. 
Interestingly, in Latin America, the frequency of KRAS 
mutations was as low as 14%. These results corroborate 
the importance of racial differences in the oncogenic 
driver gene mutations and could explain the higher 
incidence of EGFR mutations in Spain than in other 
European countries such as France or Germany. In a recent 
report, different EGFR and KRAS mutational ratio across 
South America was reported, and, allegedly, the migration 
of population through the Bering Strait could account for 
this observation [49].
Such migrations could explain the variations in the 
incidence of driver oncogene mutations across populations, 
and shed light on the importance of ethnic background to 
favour some genetic testing in subpopulations with the aim 
of increasing the number of patients who could benefit 
from targeted therapies.
Ethnic minorities in France, similarly to the rest 
of the European Community, tend to have immigrated 
mostly from Africa, rather than from Asia, contrarily 
to what observed in North America or Oceania. As a 
consequence, our unselected consecutive population 
included a higher proportion of Africans (10.8%) than of 
Asians (1.8%). Furthermore, smoking habits, especially 
in women, are probably different between ethnic groups, 
with 1st or 2nd generation North-Africans females being 
unlikely smokers. This social context could influence 
the mutational spectra of NSCLC diagnosed in French 
metropolitan areas in different ethnic subgroups and 
genders.
Our study, albeit large, has several limitations. 
Firstly, the assignment of ethnicity in this study was 
potentially prone to contain mistakes, yet it was based 
on the objective evaluation of birth places of the patient 
and of his/her parents. Indeed, French legislation forbids 
to record the ethnic origin of the patients. Hence, we 
were compelled to assume the ethnicity of each patient 
by considering the Country of birth. However, in the 
globalized world context, we fully acknowledge that the 
birthplace does not necessarily guarantee the ethnicity 
of the person. Nevertheless, by estimating the ethnic 
origin of each patient as that of the largest proportion of 
the population in the Country of birth, we can presume 
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to have minimised the mismatches, albeit doubtlessly 
present, in our study. Moreover, our study population 
included a relatively low proportion of non-white 
Europeans, despite the multicultural milieu observed in 
the greater Paris region nowadays. In particular, given the 
relatively small number of patients of Asian descent in our 
study, the estimation of the frequency of rare mutations 
across subgroups could be rather imprecise. The rather 
low proportion of non-Europeans could be due to the 
age distribution, with several retired immigrants having 
decided to move back to their home Countries, while the 
younger ones remaining in France have not yet developed 
lung cancer. Furthermore, given the real-life approach 
of our study, we gathered data from several pathology 
centres, and some missing data could have occurred, 
especially concerning smoking habits. Nevertheless, our 
heterogeneous population encompasses all consecutive 
patients we could retrieve, without any selection except 
histology and exploitable tissue, thus reducing possible 
bias. Moreover, all our samples were analyzed by the same 
molecular platform within a relatively short time span, 
thus minimizing technical differences related to equipment 
or manpower.
In conclusion, we show interesting and clinically 
relevant variations of activating somatic mutations that 
are targetable in subgroups of patients according to the 
gene and patient’s birthplace. In particular, African 
women exhibit molecular profiles in their tumor closer 
to those of Asian than Caucasian women, and they could 
dramatically benefit from anti-EGFR and anti-ERBB2 
targeted therapies.
PATIENTS AND METHODS
This study was conducted in France during daily 
clinical practice for somatic EGFR mutations research and 
involved clinicians, pathologists and biologists. Clinical 
and biological dataavailable in patients’ medical records 
werecollected by the physician in charge of the patient. 
All the data were centralized in a database and made 
completely anonymous. The database has been declared 
to the CNIL (Commission nationale de l'informatique et 
des libertés; French dataprotection authority).
The study was conducted on a total of 2,240 
consecutive patients with newly-diagnosed, histologically-
proven metastatic or recurrent NSCLC and tested for 
EGFR mutational status in the routine clinical setting 
using the same somatic genetic testing strategy, between 
November 2011 and December 2013.
Mutational testing was performed at a single 
platform with expertise in both molecular and pathological 
diagnostics. The platform was ISO 15189 (for screening 
and identification of mutations in EGFR, KRAS and 
BRAF) and INCa (French National Institute of Cancer) 
certified. ALK or ROS1 translocations were not included 
in the analysis.
Age, gender and birthplace, collected by physicians 
at the first visit, were mentioned in the medical record 
of each patient. When birthplace was not specified in 
the medical record, it was found out from the personal 
identity number at the French Health care system (Sécurité 
sociale). For African or Asian descendants who were 
born in France, parents’ birthplace was considered when 
mentioned in the medical record. If this information was 
not available, patients were excluded from the study. Thus, 
full data were available for a total of 2,219 patients (out of 
2,240), which were included in the analysis.
Patients were classified according tosSmoking status 
as never smokers, former smokers (≥ 5 years of quitting) 
or active smokers (including recent quitters, light or heavy 
smokers, with a cut off at 10 pack/years) and the number 
of pack/years of smoking (one pack/year is defined as 20 
cigarettes per day during 1 year) was retrieved [50, 51].
Histology was assessed by specialist lung cancer 
pathologists using the WHO criteria, and adenocarcinoma 
described according to the International Association for 
the Study of Lung Cancer classification [52]. Histological 
type and grading was defined using haematoxylin and 
eosin (HE)-stained biopsies after serial sectioning. 
Immunohistochemistry used the recommended panel 
of antibodies for classification of NSCLC (TTF1, CK7, 
CK5/6 and/or p63). Clinico-pathological stage was 
assigned according to the 7th edition of the tumor-node-
metastasis classification [53]. Squamous cell carcinoma 
samples were excluded from the study.
Mutational status analysis was performed using 
formalin-fixed and paraffin-embedded tumours containing 
more than 10% of cancer cells. DNA was extracted after 
overnight paraffin digestion at 56°C. All the known 
activation and resistance gene abnormalities in EGFR 
exons 18 to 21, KRAS exons 2 and 3, BRAF exons 11 and 
15, ERBB2 exon 20 and PI3KCA exons 9 and 20 were 
screened. Genetic abnormalities were analysed using a 
combination of technologies. The screening of these gene 
abnormalities was performed for each exon using a High 
Resolution Melting (HRM) technology (Lightcycler 480, 
Roche), together with a concomitant search by allelic 
discrimination for the 7 most frequent gene abnormalities 
in KRAS exons 2 and 3; EGFR (L858R) and BRAF 
(V600E). Base pairs deletion in exon 19 of EGFR were 
analysed by fragment analysis (ABI 310, Applied). When 
gene abnormalities, especially uncommon mutations, were 
not observed by HRM, but only using the other techniques 
of identification, a Sanger sequencing was performed.
All sequence analyses were checked for plausibility. 
All techniques are broadly accepted for routine detection 
of EGFR mutational status. The laboratory of molecular 
pathology successfully completed the round robin test of 
the French quality initiative certified Societies [54]. It also 
got the ISO 15189 certification in 2013 for the screening 
and the identification of the EGFR, KRAS and BRAF 
mutations.
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Statistical analysis
We used percentages for qualitative variables and 
mean and standard deviations for quantitative variables. 
Multivariate binary logistic regression was used to 
determine the independent predictive factors for the 
occurrence of specific mutations. In case of missing data 
(especially for smoking status), cases were excluded from 
the model. Differences in clinical characteristics according 
to ethnic origin were explored using Student’s t or chi-
squared tests. Significance was determined by a P-value 
< 0.05. All statistics were performed using SPSS software 
(SPSS version 17.0 for Windows, IBM Inc., Chicago, IL, 
USA).
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